TCL Archive NIH Grant Funding to Use Percentiles Instead Of Priority Scores; Minimal Impact Seen By NCI January 22, 1988
TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive NCI Plans $38 Million For New Research In Tobacco Control Over Next Two Years October 16, 1998